Ankyra in the News
Press Releases
Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN‐101
March 26, 2024 (Cambridge, MA) – Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101). JEN-101 is a first-in-class, pre-clinical immuno-oncology agent...
Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors
Safety and tolerability to be determined at up to 10 study sites in the United States and Canada CAMBRIDGE, MA – March 5, 2024 – Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first...
Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models
Pre-clinical studies of ANK-101, an anchored IL-12 therapy, demonstrate the potential of anchored immune medicines to enhance the efficacy and safety profile of cancer immunotherapies CAMBRIDGE, MA – December 12, 2023 (BUSINESSWIRE) – Ankyra Therapeutics, an emerging...
Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma
ANK-101 is a novel first-in-class anchored IL-12 immunotherapy designed for limited anchored delivery to increase immune cell infiltration into tumors and may further increase responses to immune checkpoint inhibitors CAMBRIDGE, MA – November 13, 2023 (BUSINESSWIRE) –...
Ankyra Therapeutics Announces Promising Preclinical Data on ANK-101, a Novel Anchored Immune Medicine, in Combination with Cytotoxic Chemotherapy in Head and Neck Cancer Model
First-in-class anchored IL-12 immunotherapy mANK-101 shows tumor growth delay in murine models as a monotherapy and in combination with platinum and anti-PD-1 Data presented at the Society for Immunotherapy of Cancer in San Diego pave the way for ANK-101 as...
Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors
Clearance from U.S. Food & Drug Administration and Health Canada permits Phase I open-label dose escalation study to begin in first quarter of 2024 IL-12- based anchored immunotherapy increases immune cell infiltration into tumors while decreasing systemic...
